COMMUNIQUÉS West-GlobeNewswire

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
09/02/2026
WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical [...]
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
09/02/2026
Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company [...]
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
09/02/2026
Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel [...]
Argá Medtech Reports 94% Lesion Durability and Strong Safety Profile in First-in-Human BURST-AF Trial of Single-Catheter PFA System
09/02/2026
Coherent Sine-Burst Electroporation™ Platform demonstrates 100% procedural success and high freedom from AF in paroxysmal and persistent patients COHERENT-AF U.S. Investigational Device Exemption (IDE) clinical study [...]
The Oxford-Harrington Rare Disease Centre Advances Discovery of Therapies for Friedreich’s Ataxia (FA)
09/02/2026
Philanthropic funding from the FA Alliance Innovation Fund awarded to five Oxford researchers to support development of novel therapeutics OXFORD, UK and CLEVELAND, Ohio, US, 9 th February 2026 – The Oxford-Harrington [...]
Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
09/02/2026
ROCKVILLE, Md. and SUZHOU, China, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company, a global, commercial stage, integrated [...]
Omada Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 5, 2026
09/02/2026
SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its fourth quarter and full year 2025 results on Thursday [...]
Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping
09/02/2026
SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This virtual symposium [...]
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
09/02/2026
New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026 [...]
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
09/02/2026
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the [...]
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
09/02/2026
VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
09/02/2026
– First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million – First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million – Conference [...]
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
09/02/2026
MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Kraig Biocraft Laboratories Poised for Explosive Spider Silk Production Growth
09/02/2026
2026 Production Plan Set for a Record 10 Metric Tons of Recombinant Spider Silk Cocoon Per Month ANN ARBOR, Mich., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig [...]
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
09/02/2026
Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd [...]
Avis aux médias : La journée Tout le monde en rouge attire l’attention sur la crise des maladies cardiaques chez les femmes au Canada
09/02/2026
OTTAWA, Ontario, 09 févr. 2026 (GLOBE NEWSWIRE) -- Le 13 février, la population canadienne célébrera la Journée Tout le monde en rouge , une campagne nationale de sensibilisation à la santé cardiaque des femmes. [...]
Media Advisory: Wear Red Canada highlights heart disease crisis facing Canadian women
09/02/2026
OTTAWA, Ontario, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Canadians will mark Wear Red Canada Day on February 13, a national awareness initiative focused on women’s heart health. Why: Heart disease is the leading cause of [...]
SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy
09/02/2026
All patients dosed with SPVN06 in Phase I/II trial continue to demonstrate a favorable safety profile Initial data readout for this novel gene-agnostic therapy expected in 2027 Paris, February 9, 2026 – SparingVision (“ [...]
Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®
09/02/2026
Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at risk Novo Nordisk takes decisive legal action to stop Hims [...]

Pages